Wilmington, NC – More major recognition for Thermo Fisher Scientific since acquiring PPD of Wilmington.
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been named “Best Vaccine CRO” at the Asia Pacific Vaccine Excellence Awards 2022 organized by IMAPAC for the second consecutive year, recognizing the business’ contribution to helping customers develop safe, effective vaccines.
The award honors the contract research organization (CRO) within Asia-Pacific that has engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality and safety in vaccine development and manufacturing amid the global pandemic.
Leaders of the business accepted the award during a ceremony at the fourth Vaccine World Asia Congress held in Singapore. The annual event, which attracts hundreds of representatives from Asia’s top vaccine and supply chain companies, brings together global partners and regional stakeholders to leverage partnership opportunities, discuss technological advancements and spearhead scientific innovation.
“This recognition underscores our reputation as a world leader in supporting our customers’ vaccines research and our ability to provide deep expertise in Asia Pacific,” said Les Enterline, senior vice president, vaccines, clinical research, Thermo Fisher Scientific. “As the clinical research business of Thermo Fisher, we remain committed to quality delivery, and we will continue to expand in Asia-Pacific to serve local and global customers with their clinical research initiatives.”
The PPD clinical research business utilizes development capabilities and expertise within vaccine development to help customers attend to the unique needs of vaccine trials and accelerate development with proven solutions and dedicated resources. Services can be tailored across trial phases, for localized or global studies, for biotech and large pharmaceutical companies and not-for-profit and governmental programs.
Vaccine development services are available across six continents with local expertise in all regions, including Asia-Pacific. The PPD clinical research business has 20 years of local experience in the region and provides a broad range of Phase I-IV services, including clinical monitoring, project management and patient recruitment.
Source: Nadine Maeser, Thermo Fisher Scientific
